Healthcare
Tiziana Life Sciences Ltd(TLSA)
Live Price
Offline$1.16
+7.41% today
1Y Change
-29.03%
Window
Jun 23, 2025 โ Jun 12, 2026
- Market Cap
- โ
- Revenue Growth
- 0.0%
- EPS Growth
- +35.3%
- Dividend Yield
- 0.0%
Coverage: 245 bars ยท Jun 23, 2025 โ Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Tiziana Life Sciences Ltd (TLSA) is a Healthcare stock with listed on NASDAQ. The stock last traded around $1.16 and down 29.0% across the available one-year price window (Jun 23, 2025 โ Jun 12, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +35.3%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +35.3%, free cash flow +90.1% with operating margin 0.0% and ROIC -41.2%. Stock Foundry combines TLSA price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report came in below the EPS bar
2026 was reported on May 1, 2026 with an EPS surprise of -143.0%.
The setup is mixed rather than one-directional
Revenue is 0.0% and EPS is +35.3%, while operating margin sits near 0.0%.
The next real check-in already has a date
The next earnings event is scheduled for Oct 7, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 2 reported quarters, the stock averaged +5.0% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 1, 2026 | -143.0% | +3.7% | +17.9% | +4.5% |
2025 Oct 13, 2025 | โ | +0.5% | -8.0% | -17.8% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TLSA
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
TLSA Max Drawdown
-56.00%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for TLSA and SPY.
Company Overview
Tiziana Life Sciences Ltd
NASDAQ Global Market
Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti-Interleukin 6 receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. The company was incorporated in 1998 and is headquatered in London, the United Kingdom.
- Leadership
- Ivor R. Elrifi
- IPO Date
- Nov 20, 2018
- Employees
- 9
- Street Address
- 55 Park Lane
- Mailing
- London, W1K 1NA
- Region
- London, GB
- Reporting Currency
- USD
- Investor Line
- 44 20 7495 2379
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- 2.3
- Price/Sales
- โ
- Price/Book
- 2.4
Growth
- Revenue
- 0.0%
- EPS
- +35.3%
- Free Cash Flow
- +90.1%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -125.8%
- ROIC
- -41.2%
Balance Sheet
- Debt/Equity
- 0.01
- Current Ratio
- 8.79
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.